作者
C Roddie, J Dias, M O’Reilly, L Green, M Vaughan, G Agliardi, J Garcia, E Lewin, M Lowdell, M Mitsikakou, E Charalambous, A Hotblack, H Dreau, M Marzolini, L Wood, C Every-Clayton, A Lal, Y Ngai, B Popova, A Malhi, S Kunaseelan, V Spanswick, H Lowe, L Ensell, J Hartley, S Domning, L Thorne, H Hyare, P Murphy, D Linch, C Fox, K Peggs, K Cwynarski, M Pule
发表日期
2022/6/1
期刊
HemaSphere
卷号
6
页码范围
1342-1343
出版商
LWW
简介
Background: Relapsed/refractory (r/r) primary central nervous system lymphoma (PCNSL) has a median overall survival of 2-8 months and few therapeutic options. CD19 CAR-T therapy is highly effective for systemic B-cell lymphoma, but associated neurotoxicity has led to exclusion of PCNSL patients from pivotal clinical trials. We have previously described AUTO1, a CD19 CAR with a fast off-rate CD19 binding domain, designed to reduce immune toxicity and improve engraftment. Its clinical activity has been tested in r/r paediatric and adult B-ALL, NHL and CLL, with high remission rates, low incidence of CRS/ICANS despite CAR trafficking into the cerebrospinal fluid (CSF) and long-term CAR-T engraftment.
Aims: Based on these favourable characteristics, we initiated the CAROUSEL study of AUTO1 in PCNSL (NCT04443829), testing both intravenous (IV) and intraventricular (I-VEN) routes of CAR-T delivery. We …
学术搜索中的文章
C Roddie, J Dias, M O'Reilly, L Green, M Vaughan… - HemaSphere, 2022